CD40LG and primary progressive multiple sclerosis: Motivated by this, we investigated the proteomic profile of untreated patients with SPMS and PPMS, effects of natalizumab and methylprednisolone treatment, and associations with IgM OCBs, identifying treatment-responsive biomarkers in PMS and further characterizing the subsets of patients with IgM OCBs.